Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
Status:
Completed
Trial end date:
2016-06-20
Target enrollment:
Participant gender:
Summary
This international study is a prospective noninterventional observational cohort study of
patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine
treatment conditions to prevent stroke or non-central nervous system systemic embolism.
Patients will be followed up for 1 year or until 30 days after end of rivaroxaban therapy in
case of therapy was discontinued earlier than 12 months. Serious adverse events will be
followed up adequately. Laboratory values (e.g., Hb, HCT, haemoccult) should be documented
for each point in time they were measured.